Description: Taysha Gene Therapies, Inc., a gene therapy company, develops adeno-associated virus based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; TSHA-102 for the treatment of Rett syndrome; TSHA-103 for the treatment of SLC6A1 haploinsufficiency disorder; and TSHA-104 for the treatment for Surfeit locus 1 deficiency. The company also has strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. Taysha Gene Therapies, Inc. was founded in 2019 and is based in Dallas, Texas.
Home Page: www.tayshagtx.com
TSHA Technical Analysis
3000 Pegasus Park Drive
Dallas,
TX
75247
United States
Phone:
214 612 0000
Officers
| Name | Title |
|---|---|
| Mr. R. A. Session II | Founder, Pres, CEO & Director |
| Mr. Kamran Alam CPA, M.B.A. | Chief Financial Officer |
| Dr. Suyash Prasad FFPM, M.Sc., MBBS, M.D., M.B.B.S., F.F.P.M | Chief Medical Officer and Head of R&D |
| Mr. Frederick Porter Ph.D. | Chief Technical Officer |
| Mr. Jim Rouse | Chief Information Officer |
| Ms. Tracy M. Porter | Chief People Officer |
| Ms. Emily McGinnis M.P.H. | Chief Patient Officer & Head of Gov. Affairs |
| Ms. Mishima Gerhart | Chief Regulatory Officer & Head of Quality |
| Mr. Sean McAuliffe | Chief Commercial Officer |
| Mr. Greg Gara | Sr. VP of Manufacturing |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 13.3011 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-09-24 |
| Fiscal Year End: | December |
| Full Time Employees: | 178 |